Tenaya Therapeutics
NASDAQ: TNYASouth San Francisco, US · Founded 2016 · Incorporated in Delaware · 93 employees on LinkedIn · 3 known investors
Find your way into Tenaya Therapeutics
743 people in our graph share verified history with the Tenaya Therapeutics team — schools, employers, funds. One of them is your warm intro.
Deep Nisharunlockedknows Bruce R. Conklin, M.D. · together at J David Gladstone Institutes (overlapped)
×2knows the team · via Glastone Institutes
knows the team · via University of California, San Francisco
knows the team · via Northwestern University - Kellogg School of Management
knows the team · via Amgen
knows the team · via University of California, Berkeley
Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease. This page is a board/leadership team bio page.
Founders & leadership
Tenaya Therapeutics was founded in 2016 by Deepak Srivastava, M.D., Eric Olson, Ph.D., Bruce R. Conklin, M.D., Sheng Ding, Ph.D., and Saptarsi Haldar, M.D..
DS
Deepak Srivastava, M.D.inCo-Founder and Chair, Scientific Advisory Board
EO
Eric Olson, Ph.D.𝕏Scientific Founder
BR
Bruce R. Conklin, M.D.inCo-FounderBruce R. Conklin is a physician-scientist and investigator at Gladstone Institutes, as well as a professor of medicine, ophthalmology, and pharmacology at UCSF, where he also serves as deputy director of the Innovative Genomics Institute. He specializes in stem cell research and genome engineering.
SD
Sheng Ding, Ph.D.Scientific Founder
SH
Saptarsi Haldar, M.D.inScientific Co-Founder2016–2018Saptarsi Haldar is a physician and cardiologist with experience spanning academic medicine, biotech, and pharmaceutical development, with expertise in drug discovery, translational research, and clinical practice.
EH
Eric HyllengreninChief Financial OfficerHe previously served as CFO and EVP at Zura Bio and as CFO and COO at Atara Biotherapeutics, where he oversaw over $500 million in public financings, and spent fifteen years in finance, investor relations, and business development roles at Amgen. He holds a B.B.A. in finance and Russian from the University of Notre Dame and an M.B.A. in finance from Northwestern University's Kellogg School of Management.
FA
Faraz Ali, MBAChief Executive Officer
Investors · 3
Valuation · disclosed
Disclosed events$589.9Mvaluation at IPOJul 2021 · $15.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 1
by search overlap
Companies competing with Tenaya Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Tenaya Therapeutics do?
- Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease. This page is a board/leadership team bio page.
- Who founded Tenaya Therapeutics?
- Tenaya Therapeutics was founded by Deepak Srivastava, M.D., Eric Olson, Ph.D., Bruce R. Conklin, M.D., Sheng Ding, Ph.D., Saptarsi Haldar, M.D. in 2016.
- Who are Tenaya Therapeutics's investors?
- Tenaya Therapeutics's investors include GV (Google Ventures), The Column Group, venBio Partners.
- Where is Tenaya Therapeutics headquartered?
- Tenaya Therapeutics is headquartered in South San Francisco, US.